Tuesday 10 November 2020

The Brewery, London EC1

2020 Shortlist review

Back | Best Communication Award | Breakthrough of the Year AwardBest Technology Award
Mediscience Commentator of the Year Award | Capital Market Transaction of the Year Award
Most Significant Contribution to the Mediscience Sector Award The Emerging Star Award
Chief Executive of the Year Award | Company of the Year Award 


Capital Market Transaction of the Year Award

Sponsored by SP Angel

Criteria 

This award recognises a significant capital market transaction during our period under review. The capital market transaction could be an IPO or a follow-on financing; it would be significant in scope and transformational in nature and would materially enhance the prospects for the business in the short, medium and long term.

In deciding the shortlist and eventual winner, the Voting Panel will take into account the amount raised, stock price performance and the quality of the share register. 

 


EMA20_Shortlist-logo_AmrytPharma.png

Amryt Pharma plc 

www.amrytpharma.com

Also shortlisted for the Breakthrough of the year Award, 2019/2020 has been a sensational year for Dublin-based Amryt Pharma.

In September 2019, Amryt completed the acquisition of US based Aegerion Pharmaceuticals in what the Voting Panel described as “one of the most complex Capital Market transactions ever seen”. The deal involved Amryt reversing into a significantly larger company, that had previously filed for Chapter 11 bankruptcy, whilst also raising $60m in equity.

The result of the transaction has rapidly transformed Amryt from a one-product company to having two commercialised products, a US salesforce and enhanced global market reach, establishing the group as an international player in the orphan disease space.

 
EMA20_Shortlist-logo_Galapagos.png

Galapagos NV 

www.glpg.com

Galapagos has been shortlisted in no less than three categories at the 2020 awards, demonstrating the magnitude of the group’s achievements in the period.

In July last year, Galapagos entered into a transformative 10-year global research and development collaboration with US antiviral drugmaker, Gilead, allowing the group to access all Galapagos’ current and future programs outside of Europe.

Gilead invested $5.1bn in the major expansion of its partnership with the group, resulting in shares in Galapagos rising to an all-time high. The Voting Panel agreed that not only was the deal transformational for Galapagos, it also reflected well on the whole European biotech sector.

 

Genmab A/S 

www.genmab.com

Another triple shortlisting for Genmab, Europe’s largest independent biotech, which also had a transformative and record-breaking year.

In July last year, Genmab raised $582m in Europe’s largest ever Nasdaq IPO, giving the group a market cap of $11.6bn. The group reached its current position based on two approved products: Arzerra, sold by Novartis; and its blockbuster blood cancer drug, Darzalex, developed in partnership with Janssen.

The funds raised have allowed Genmab to accelerate its pipeline of differentiated and well-tolerated antibodies alongside its approved products via alliances.

  

 
EMA20_Shortlist-logo_Genmab.png
 
EMA20_Shortlist-image_Breakthrough_Genmab.png 

 
EMA20_Shortlist-logo_MorphoSys.png

MorphoSys AG 

www.morphosys.com

Munich-based MorphoSys has a focus on cancer, and, together with its partners, the group has developed more than 100 product candidates, of which 28 are currently in clinical development

In January 2020, MorphoSys signed a unique $2bn global collaboration and licence agreement with Incyte, for its lead candidate, tafasitamab. The deal triggered an upfront payment of $750m plus an equity investment from Incyte of $150m. In addition, MorphoSys is eligible to receive milestone payments totalling up to $1.1bn, making it transformational for the group.

MorphoSys and Incyte will co-commercialise tafasitamab in the US, with MorphoSys leading the commercialisation strategy.